Drug Trial Radar · NCT03069508
Clemizole HCl for Subjects With Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Planned (sponsor's estimate)
Start
Feb 13, 2017
Primary completion
Dec 31, 2017
Study completion Jan 31, 2018
Sponsor
- Lead sponsor
- Eiger Group International, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.
Conditions
- Hepatocellular Carcinoma
Interventions
Clemizole HydrochlorideDrug
Clemizole Hydrochloride will be administered orally for up to 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: Number of recorded adverse events at six months
- Overall tumor response according to radiologic assessments associated with clemizole HCl.Time frame: Change from baseline up to 24 weeks
- AUC Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)Time frame: 0-pre-dose, post dose: 15 min, 30 min, 60 min, 90 min, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours post oral administration of clemizole HCl for those subjects participating in the PK portion of this trial
- Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)Time frame: 0-pre-dose, post dose: 15 min, 30 min, 60 min, 90 min, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours post oral administration of clemizole HCl for those subjects participating in the PK portion of this trial
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Ankara
Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.